Hanon O, Laroche P, Vidal J-S, Pannier B, Postel-Vinay N, Vaisse B, Girerd X
Comité français de lutte contre l'hypertension artérielle (CFLHTA), 5, rue des Colonnes-du-Trône, 75012 Paris, France.
Ann Cardiol Angeiol (Paris). 2012 Jun;61(3):218-23. doi: 10.1016/j.ancard.2012.05.002. Epub 2012 May 23.
To evaluate the blood pressure (BP) control and the efficacy of antihypertensive monotherapy using home BP self-measurement in a French population of treated hypertensive subjects in 2007 2009 and 2010.
The French League Against Hypertension Surveys (FLAHS) are conducted among a representative sample of individuals aged 35 years and older living in France. For the 2007, 2009 and 2010 surveys, a sample of 1467 subjects who owned a BP self-measurement device and performed three consecutive morning BP measurements were included. Among the 60% of subjects who reported taking at least one antihypertensive drug, we analyzed subjects treated with one of the following antihypertensive monotherapy, i.e., beta-blocker (BB), ACE inhibitors, calcium channel blocker (CCB) and angiotensin receptor blockers (ARB).
Among treated hypertensive subjects (n=886), 66% (n=586) had home BP below the 140/90mmHg threshold and 50% (n=449) below 135/85mmHg. Three hundred two subjects were treated with a single antihypertensive drug, 33% had ARB, 25% BB, 19% CCB and 13% ACE inhibitors. Age (years) for each treatment group is different (P<0.01) CCB (72.1±9.3), BB (65.6±9.8), ARB (68.6±8.9) and ACEI (67.3±10.2). The mean systolic/diastolic BP (mmHg) is not comparable between monotherapy 130.7/76.1 (ARB), 130.7/78.7 (BB), 134.0/75.2 (CCB) and 139.1/80.3 (ACEI) for ARB, BB, CCB and ACE inhibitors respectively. Compared to ACE inhibitors, BP was significantly lower with ARB (P<0.01). The proportion of subjects with a BP below 140/90mmHg was 73% for ARB, 52% for BB, 68% for CCB and 47% for ACE with a statistical significance (P=0.03) for ARB vs. ACEI and CCB vs. ACEI.
Among subjects treated for hypertension who owned a BP self-measurement device, 50 to 66% had a controlled BP (depending on the threshold used). It is observed differences between antihypertensive efficacy of monotherapy with a larger number of patients controlled with ARB or CCB.
评估2007年、2009年和2010年法国接受治疗的高血压患者群体中，使用家庭血压自我测量法进行血压（BP）控制及抗高血压单药治疗的疗效。
法国高血压防治联盟调查（FLAHS）针对居住在法国的35岁及以上具有代表性的个体样本开展。在2007年、2009年和2010年的调查中，纳入了1467名拥有血压自我测量设备且连续三个早晨进行血压测量的受试者。在报告至少服用一种抗高血压药物的60%受试者中，我们分析了接受以下抗高血压单药治疗之一的受试者，即β受体阻滞剂（BB）、血管紧张素转换酶抑制剂、钙通道阻滞剂（CCB）和血管紧张素受体阻滞剂（ARB）。
在接受治疗的高血压受试者（n = 886）中，66%（n = 586）的家庭血压低于140/90mmHg阈值，50%（n = 449）低于135/85mmHg。302名受试者接受单一抗高血压药物治疗，其中33%使用ARB，25%使用BB，19%使用CCB，13%使用血管紧张素转换酶抑制剂。各治疗组的年龄（岁）不同（P<0.01），CCB组（72.1±9.3）、BB组（65.6±9.8）、ARB组（68.6±8.9）和血管紧张素转换酶抑制剂组（67.3±10.2）。ARB、BB、CCB和血管紧张素转换酶抑制剂单药治疗的平均收缩压/舒张压（mmHg）不可比，分别为130.7/76.1（ARB）、130.7/78.7（BB）、134.0/75.2（CCB）和139.1/80.3（血管紧张素转换酶抑制剂）。与血管紧张素转换酶抑制剂相比，ARB治疗的血压显著更低（P<0.01）。血压低于140/90mmHg的受试者比例，ARB组为73%，BB组为52%，CCB组为68%，血管紧张素转换酶抑制剂组为47%，ARB与血管紧张素转换酶抑制剂、CCB与血管紧张素转换酶抑制剂相比具有统计学意义（P = 0.03）。
在拥有血压自我测量设备的高血压治疗受试者中，50%至66%的血压得到控制（取决于所使用的阈值）。观察到单药治疗的抗高血压疗效存在差异，更多患者使用ARB或CCB控制血压。
